[
  {
    "ts": "2026-01-31T05:09:15+00:00",
    "headline": "Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts",
    "summary": "Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government’s TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these...",
    "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-partnerships-oncology-050915165.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "34ccbb37-ccd1-3311-938d-2172535f701e",
      "content": {
        "id": "34ccbb37-ccd1-3311-938d-2172535f701e",
        "contentType": "STORY",
        "title": "Pfizer Reshapes Portfolio With New Partnerships Oncology Push And Pricing Shifts",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) licensed Novavax’s Matrix-M adjuvant technology to support future vaccine development. The company received FDA Breakthrough Therapy Designation for a combination of Sutent and bezuclastinib in gastrointestinal cancer. Pfizer agreed to provide significant drug discounts under the U.S. government’s TrumpRx initiative. Management is refocusing R&D and capital toward oncology and obesity through targeted investments and acquisitions. For investors watching NYSE:PFE, these...",
        "pubDate": "2026-01-31T05:09:15Z",
        "displayTime": "2026-01-31T05:09:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-partnerships-oncology-050915165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-reshapes-portfolio-partnerships-oncology-050915165.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NVAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]